Apr 27, 2010 ... Merck & Co., Inc. v. ... Joint Appendix Volume I · Brief for Respondent Richard
Reynolds, et al. Reply Brief for Petitioner Merck & Co. ... Brief for Dr. Harlan M.
Krumholz and Dr. Joseph S. Ross in Support of Respondents ...
Parties, docket activity and news coverage of federal case Bristol-Myers Squibb
Co. et al v. Merck & Co Inc., case number 1:14-cv-01131, from Delaware Court.
Del Giudice et al v. Harlan et al ... Company v. National Union Fire Insurance
Company of Pittsburgh, PA et al ... Docket Number: 1:2011cv04947. Urena v.
Swiss Post Solutions, Inc. et al. Date: September 21 ..... Merck & Co., Inc. v.
[ 05-4217 ] Mary Plubell v. Merck & Co., Inc. [ 05-4489 ] ... [ 06-1904 ] Douglas
Wood, et al. v. Foremost Insurance ..... [ 09-2769 ] United States v. Suresh Harlan
Harlan M Krumholz, Harold H Hines Junior professor of medicine and ...
Rofecoxib (Vioxx) was introduced by Merck in 1999 as an effective, safer .....
Letter re: financial disclosure for Merck and Co, Inc sponsored protocol entitled: ...
et al. re: fw: for review [peer]: 2001-ms-2470 (full paper) - due date Monday, 27
Harlan Fiske Stone Scholar (1985-86) ... West-Ward Pharmaceuticals, Inc. et al.;
Yamane v. .... 180 days of marketing exclusivity for its generic version of Merck's
blockbuster drug Zocor following Merck's request to remove the patents claiming
Nov 23, 2009 ... Merck, the maker of rofecoxib, promoted it as a safer alternative to .... plaintiffs
and against Merck and Co., Inc. While the authors obtained access to the .... Our
analysis builds upon the prior work of Jüni et al., published shortly .... Cona v.
Merck and Co., Inc.] 2000. Mar 9 [Last Accessed December 1, 2008].
Aug 19, 2008 ... During Cona v Merck and Co., Inc., and McDarby v Merck and Co., Inc., .....
Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. ..... MD, MHS;
Joseph S. Ross, MD, MHS; David S. Egilman, MD, MPH; and Harlan M.
Nov 23, 2009 ... ... MHS; David S. Egilman, MD, MPH; Yongfei Wang, MS; Harlan M. Krumholz,
MD, SM ... Merck & Co Inc, Whitehouse Station, New Jersey (hereinafter, ..... Our
analysis builds on the prior work of Jüni et al, published shortly after .... of the
COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis.
Documents were identified that suggested the company was tracking and .... less
common in the naproxen group than in the rofecoxib group (0.1 percent vs. .....
request of plaintiffs in litigation against Merck and Co., Inc. related to rofecoxib in
the United States from 2006 to 2007. ... Bhandari M, Busse JW, Jackowski D. et al